You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The increased forecast is the result of continuing COVID-19 testing volumes along with recovery in its breast and skeletal business, Hologic said.
The company is developing a blood-based test to detect more than 50 cancer types across all stages and identify a tumor's tissue of origin.
The company, which went public in June, has had to deal with issues with the US DOJ, and some private insurers. Its CEO's tenure at Sequenom was also marred by a scandal.
The company recently agreed to pay millions to three major insurers under settlement agreements related to allegations over undisclosed past business practices.
The Beijing-based company offers genomics products and services, including PCR instruments and cancer sequencing, and maintains a research center in the US.
The firm said it intends to use the credit facility to support its US and European commercial paper programs and for general corporate purposes.
ArcherDx has leveraged next-generation sequencing to develop and commercialize more than 325 research-use-only products and a pan-solid tumor diagnostic test.
The company also inked a deal with an investment bank to publicly offer from time to time up to $4.2 million of its stock.
The Seattle-based immune sequencing firm will not receive any proceeds from the sale of the shares.
The firm plans to raise as much as $250 million, according to the document filed with the US Securities and Exchange Commission.